晚期非小细胞性肺癌EGFR敏感突变患者一线化疗后序贯EGFR-TKI的疗效  

Sequential therapy of first-line chemotherapy and EGFR-TKI in patients of advanced non-small cell lung cancer with mutated EGFR

作　　者：赖敏 莫诗瑶 LAI Min;MO Shiyao(The Affiliated Shenzhen Hang Seng Hospital of Southern Medical University,Shenzhen 518102,China;Maoming Municipal People's Hospital,Maoming 525000)

机构地区：[1]南方医科大学附属深圳恒生医院,广东深圳518102 [2]茂名市人民医院

出　　处：《包头医学院学报》2018年第4期44-46,共3页Journal of Baotou Medical College

摘　　要：目的:研究晚期非小细胞肺癌EGFR敏感突变患者一线化疗后序贯表皮生长因子受体-酪氨酸激酶抑制剂(epidermal growth factor receptor-tyrosine kinase inhibitors,EGFR-TKI)的临床疗效。方法:选取2014年1月至2016年1月首次诊断的有表皮生长因子受体(epidermal growth factor receptor,EGFR)基因敏感突变的晚期非小细胞型肺癌患者48例,随机分为一线化疗后序贯EGFR-TKI组(观察组)和单用EGFR-TKI组(对照组),比较两组患者化疗后不良反应(白细胞减少、胃肠道反应、肝功能受损、皮疹)、生存分析指标[无进展生存期(progression-free survicval,PFS)、总生存期(overall survival,OS)]。结果:两组患者的化疗后不良反应比较差异无统计学意义(P>0.05);观察组的PFS长于对照组(P<0.05),观察组的OS长于对照组(P<0.05)。结论:一线化疗后序贯EGFR-TKI与单用EGFR-TKI相比较,不良反应未增加,但可以延长患者PFS和OS,一线化疗后序贯EGFR-TKI是治疗非小细胞型肺癌的有效方法,值得临床推广。Objective:To study the clinical effects of sequential therapy of first-line chemotherapy and epidermal growth factor receptor-tyrosine kinase inhibitors(EGFR-TKI)in patients of advanced non-small cell lung cancer with EGFR mutants.Methods:48 cases of non-small-cell lung cancer with mutated EGFR admitted from Jan.2014 to Jan.2016 were selected and randomly arranged into two groups.The side effects of chemotherapy such as leukopenia,gastrointestinal reaction,liver dysfunction and rash,and the survival analysis indexes including PFS and OS were compared between the two groups.Results:There was no significant difference in the side effects of chemotherapy between the two groups(P>0.05),but PFS and OS of the observation group were longer than those of the control group(P<0.05).Conclusion:Compared with EGFR-TKI alone,sequential therapy of first-line chemotherapy and EGFR-TKI,is an effective way to treat non-small cell lung cancer,which can prolong PFS and OS in patients,with no increase in adverse effects.It is worth the clinical application.

关 键 词：非小细胞型肺癌 EGFR-TKI EGFR 序贯疗法 

分 类 号：R734.2[医药卫生—肿瘤]